Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Transplant Proc. 2023 Apr;55(3):533-539. doi: 10.1016/j.transproceed.2023.02.048. Epub 2023 Mar 3.
During the COVID-19 pandemic, efforts to maintain solid-organ transplantation have continued, including the use of SARS-CoV-2-positive heart donors.
We present our institution's initial experience with SARS-CoV-2-positive heart donors. All donors met our institution's Transplant Center criteria, including a negative bronchoalveolar lavage polymerase chain reaction result. All but 1 patient received postexposure prophylaxis with anti-spike monoclonal antibody therapy, remdesivir, or both.
A total of 6 patients received a heart transplant from a SARS-CoV-2-positive donor. One heart transplant was complicated by catastrophic secondary graft dysfunction requiring venoarterial extracorporeal membrane oxygenation and retransplant. The remaining 5 patients did well postoperatively and were discharged from the hospital. None of the patients had evidence of COVID-19 infection after surgery.
Heart transplants from SARS-CoV-2 polymerase chain reaction-positive donors are feasible and safe with adequate screening and postexposure prophylaxis.
在 COVID-19 大流行期间,人们一直在努力维持实体器官移植,包括使用 SARS-CoV-2 阳性供心。
我们介绍了本机构在 SARS-CoV-2 阳性供心方面的初步经验。所有供者均符合本机构移植中心标准,包括支气管肺泡灌洗液聚合酶链反应结果为阴性。除 1 例患者外,其余患者均接受了抗刺突单克隆抗体治疗、瑞德西韦或两者联合的暴露后预防。
共有 6 例患者接受了 SARS-CoV-2 阳性供者的心脏移植。1 例心脏移植术后发生灾难性二次移植物功能障碍,需要静脉-动脉体外膜肺氧合和再次移植。其余 5 例患者术后恢复良好,出院。术后患者均无 COVID-19 感染证据。
通过充分的筛查和暴露后预防,从 SARS-CoV-2 聚合酶链反应阳性供者中进行心脏移植是可行且安全的。